MLAB logo

MESA LABORATORIES INC

MLABNASDAQ
πŸ† #2527 by market capEarnings Nov 5US Equity
$110.50β–Ό $0.73 (βˆ’0.66%)
Live
1hβ–² 0.8%
24hβ–Ό 0.7%
7dβ–² 7.4%
14dβ–² 11.1%
30dβ–² 16.7%
1yβ–² 74.3%
🏦Market Cap
$619M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+3.4%
Slowing
πŸ“ŠGross Margin
63.5%
High
πŸ’΅FCF Margin
15.9%
Healthy
βš–οΈP/S Ratio
2.3x
Cheap
Otter Score
57
Weak

Trading Snapshot

Day Range
$109.65 – $111.56
52-Week Range
$58.83 – $113.99
Volume
$1.83B
Avg Volume
$1.73B
Shares Outstanding
5.6M
Next Earnings
Oct 28, 2026

Fundamentals Snapshot

Annual Revenue
$249M
Last Q Revenue
$60M
P/E Ratio
84.5
P/S Ratio
2.3x
EPS (TTM)
$1.21
Dividend Yield
0.62%

Why Investors Own MLAB

  • βœ“High-growth profile β€” revenue up +38.4% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 53% gross margin and 22% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$249Mβ–² +44.4% YoY
Gross Margin (TTM)
52.9%β–² +2.4% YoY
Operating Income (TTM)
$44Mβ–² +44.4% YoY
Free Cash Flow (TTM)
$56Mβ–² +44.4% YoY

About MESA LABORATORIES INC

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
57/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy3
Buy3
Hold3
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates